Yep, the solubility of the solution is what is being changed here to prevent crystalisation/precipitation, the result of which could, at worst case, result in circulatory/organ failure (probably something important i left out).
However, I would anticipate the effect of this is more likely to have an effect on half life and dosing regime (which can be optimised) I.e. pharmacokinetics as you note.
I thought you were concerned the drug would suddenly no longer have the same function with reformulation.
I think we are likely on the same page!
Hope you have a good weekend ahead.
Ann: H1 2023 Preclinical and Clinical Programs Update, page-59
-
- There are more pages in this discussion • 61 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.69 |
Change
0.000(0.00%) |
Mkt cap ! $288.0M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.57 | $387.6K | 237.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 807 | $1.63 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.69 | 2376 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |